Blueprint Medicines
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Blueprint Medicines generated cash of -$436,847,000, which is more than the previous year. Cash used in financing activities reached the amount of $119,225,000 last year. Net change in cash is therefore -$43,380,000.
Cash Flow
| 2014 | -35.4M | -700K | 81.35M |
|---|---|---|---|
| 2015 | -31.67M | -6.07M | 153.22M |
| 2016 | -24.51M | -218.70M | 132.57M |
| 2017 | -119.86M | -75.84M | 543.94M |
| 2018 | -175.00M | -161.08M | 4.45M |
| 2019 | -278.01M | -16.46M | 340.63M |
| 2020 | 387.03M | -434.24M | 617.75M |
| 2021 | -298.65M | -225.86M | 50.71M |
| 2022 | -502.27M | -149.54M | 561.81M |
| 2023 | -436.84M | 274.04M | 119.22M |
BPMC Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 124.90M | 215.11M | 689.80M | 119.60M | 73.42M | 405.07M | 52.06M | 162.70M | 47.24M | 1.98M |
Operating activities | ||||||||||
Net income | -506.98M | -557.51M | -644.08M | 313.88M | -347.69M | -236.64M | -148.11M | -72.49M | -52.76M | -40.28M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 11.66M | 11.73M | 6.47M | 6.55M | 5.25M | 4.24M | 1.57M | 1.58M | 948K | 622K |
Stock-based compensation expense | 92.67M | 98.97M | 91.63M | 75.52M | 54.65M | 0 | 12.52M | 6.14M | 5.18M | 2.32M |
| Deferred income tax benefit | 92.67M | 98.97M | 91.63M | 75.52M | 54.65M | 0 | 12.52M | 6.14M | 5.18M | 2.32M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -7.65M | 1.57M | -18.14M | -6.38M | -599K | 198K | 3.57M | -163K | -3.41M | 0 |
Inventories | -4.36M | -8.92M | -12.56M | -6.70M | 8.97M | 0 | 6.87M | 6.93M | -78K | 0 |
Accounts payable | 1.88M | -5.81M | 4.22M | -791K | 1.44M | -445K | 1.53M | 4K | 1.39M | -512K |
Cash generated by operating activities | -436.84M | -502.27M | -298.65M | 387.03M | -278.01M | -175.00M | -119.86M | -24.51M | -31.67M | -35.4M |
Investing activities | ||||||||||
Purchases Of Investments | -766.36M | -489.70M | -655.44M | -969.43M | -738.38M | -801.23M | -360.83M | -264.46M | -1.19M | 0 |
Investments In Property Plant And Equipment | -16.06M | -8.91M | -261.24M | -3.15M | -14.01M | -12.67M | -15.51M | -2.35M | -4.88M | -700K |
Acquisitions Net | 0 | 0 | 258.15M | 431.09M | 2.45M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 274.04M | -149.54M | -225.86M | -434.24M | -16.46M | -161.08M | -75.84M | -218.70M | -6.07M | -700K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 8.19M | 50.71M | 617.75M | 327.46M | 6.42M | 547.49M | 0 | 157.07M | 268K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 97.93M | 137.78M | 0 | 0 | 0 | -1.69M | -2.58M | -3.33M | -1.80M | -750K |
Cash used in financing activities | 119.22M | 561.81M | 50.71M | 617.75M | 340.63M | 4.45M | 543.94M | 132.57M | 153.22M | 81.35M |
Net Change In Cash | -43.38M | -90.21M | -474.68M | 570.2M | 46.17M | -331.64M | 348.23M | -110.63M | 115.46M | 45.25M |
Cash at end of period | 81.52M | 124.90M | 215.11M | 689.80M | 119.60M | 73.42M | 400.30M | 52.06M | 162.70M | 47.24M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |